Shionogi’s total workforce stood at 2,117 at the end of March, down by 341 from a year before, according to its FY2023 securities filing released on June 21. The Osaka drug maker attributed the decline chiefly to its voluntary redundancy…
To read the full story
Related Article
- 301 Employees Apply for Shionogi’s Voluntary Buyout Program
November 1, 2023
- Shionogi to Cut 200 Jobs via Voluntary Buyout Program
July 11, 2023
BUSINESS
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





